The current stock price of AMRN is 15.29 USD. In the past month the price increased by 10.8%. In the past year, price increased by 21.95%.
ChartMill assigns a technical rating of 2 / 10 to AMRN. When comparing the yearly performance of all stocks, AMRN is a bad performer in the overall market: 62.58% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to AMRN. The financial health of AMRN is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months AMRN reported a non-GAAP Earnings per Share(EPS) of -0.62. The EPS increased by 65.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.12% | ||
| ROE | -18.87% | ||
| Debt/Equity | 0 |
7 analysts have analysed AMRN and the average price target is 12.24 USD. This implies a price decrease of -19.95% is expected in the next year compared to the current price of 15.29.
For the next year, analysts expect an EPS growth of 56.42% and a revenue growth 6.41% for AMRN
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.87 | 382.02B | ||
| AMGN | AMGEN INC | 15.71 | 185.02B | ||
| GILD | GILEAD SCIENCES INC | 15.76 | 160.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.56 | 117.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.65 | 78.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 716.59 | 48.28B | ||
| INSM | INSMED INC | N/A | 33.34B | ||
| NTRA | NATERA INC | N/A | 33.51B | ||
| BIIB | BIOGEN INC | 10.31 | 25.32B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.72B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.8 | 20.23B | ||
| INCY | INCYTE CORP | 16.3 | 20.55B |
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
AMARIN CORP PLC -ADR
WeWork One Central Plaza Dame Street, Dublin 2
DUBLIN Dublin 2 IE
CEO: John F. Thero
Employees: 275
Phone: 35316699020
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
The current stock price of AMRN is 15.29 USD. The price decreased by -1.42% in the last trading session.
AMRN does not pay a dividend.
AMRN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
AMARIN CORP PLC -ADR (AMRN) operates in the Health Care sector and the Biotechnology industry.
AMARIN CORP PLC -ADR (AMRN) has a market capitalization of 317.92M USD. This makes AMRN a Small Cap stock.
You can find the ownership structure of AMARIN CORP PLC -ADR (AMRN) on the Ownership tab.